Advertisement

Weight Loss May Help Prevent Multiple Myeloma

Advertisement

Key Points

  • 4.6% of overweight patients (followed for a median of 5.75 years) and 4.3% of obese patients (followed for a median of 5.9 years) developed multiple myeloma, compared with 3.5% of people at normal weight (followed for a median of 5.2 years).
  • Overweight and obese MGUS patients had a 55% and 98% higher risk of progression to multiple myeloma, respectively, than normal-weight MGUS patients.
  • African American men also were more likely than their Caucasian counterparts to experience progression from MGUS to multiple myeloma.

New research shows that excess weight increases the risk that a benign blood disorder will progress to multiple myeloma. The study, by a team at Washington University School of Medicine in St. Louis, is published in the Journal of the National Cancer Institute.

Being overweight or obese has been known to increase the risk of multiple myeloma, a cancer of the plasma cells in the blood and bone marrow that develops more often after age 60. Multiple myeloma is preceded by a blood disorder called monoclonal gammopathy of undetermined significance (MGUS), in which abnormal plasma cells produce many copies of an antibody protein. This precancerous condition does not cause symptoms and often goes undiagnosed.

“But our findings show that obesity can now be defined as a risk factor for developing multiple myeloma through this condition,” said the study's first author, Su-Hsin Chang, PhD, Assistant Professor of Surgery in the Division of Public Health Sciences at Washington University. “For patients diagnosed with MGUS, maintaining a healthy weight may be a way to prevent the progression to multiple myeloma, if further confirmed by clinical trials.”

About MGUS

MGUS is caused by elevated levels of an antibody protein, known as M protein, that is found in 3% of people over age 50. By itself, MGUS is difficult to diagnose and often does not warrant treatment.

“The diagnosis is usually made by accident, often driven by tests performed for the diagnosis or management of other conditions,” Dr. Chang said. “Although our study does not directly suggest screening for MGUS, regular checkups can help physicians monitor whether MGUS is progressing to other disorders, including multiple myeloma.”

Study Findings

The researchers analyzed data from a U.S. Department of Veterans Affairs database, identifying 7,878 patients, predominately men, diagnosed with MGUS from October 1999 through December 2009.

Among these patients, 39.8% were overweight and 33.8% were obese. The researchers then tracked whether the patients developed multiple myeloma.

They found that 4.6% of overweight patients (followed for a median of 5.75 years) and 4.3% of obese patients (followed for a median of 5.9 years) developed multiple myeloma, compared with 3.5% of people at normal weight (followed for a median of 5.2 years)—a difference that is statistically significant.

Overweight and obese MGUS patients had a 55% and 98% higher risk of progression to multiple myeloma, respectively, than normal-weight MGUS patients.

African American men also were more likely than their Caucasian counterparts to experience progression from MGUS to multiple myeloma.

“Based on our finding that being overweight or obese is a risk factor for multiple myeloma in MGUS patients, and since extra weight is a modifiable risk factor, we hope that our results will encourage intervention strategies to prevent the progression of this condition to multiple myeloma as soon as MGUS is diagnosed. Also, for [African American] people diagnosed with MGUS, close monitoring of the disease progression, in addition to maintaining a healthy weight, should be prioritized,” Dr. Chang said.

“In the future, we will look at whether healthy weight loss is inversely associated with the progression of multiple myeloma in MGUS patients or how weight change plays a role in the progression of MGUS to multiple myeloma,” he concluded.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement